ADX-2191 — Topline data
2026
Phase 3 clinical trial initiation expected H1 2026; results expected in 2026Source filing
ALDX biotech catalysts & pipeline
ALDEYRA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
ADX-246 — IND submission
2026
Investigational New Drug application expected to be submitted in 2026Source filing
ADX-248 — IND submission
2026
Investigational New Drug application expected to be submitted in 2026Source filing
reproxalap — FDA meeting
Q3 2026
The Type D meeting is expected to be held by the end of the third quarter of 2026.Source filing